ArticlePLOS global public health2024
Assessing yellow fever outbreak potential and implications for vaccine strategy.
Article in PLOS global public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Colombian protocol for the hospital management of non-critically ill patients with suspected or confirmed yellow fever.New microbes and new infections · 2026Review
- Yellow fever outbreak potential in Djibouti, Somalia and Yemen: a mathematical modelling study.BMC global and public health · 2026Article
- Article
- Evolution and spillover dynamics of yellow fever at the forest-urban interface in Brazil.Nature microbiology · 2026Article
- Yellow Fever in Pregnancy: A Comprehensive Review of the Clinical Implications and Vaccination in the Context of the 2024-2026 Americas Outbreak.Tropical medicine and infectious disease · 2026Review
- Estimating the impact of decreasing vaccination response times for outbreaks of vaccine-preventable diseases in low- and middle-income countries.BMC global and public health · 2026Article
- Estimating the historical impact of outbreak response immunisation programmes across 210 outbreaks in low and middle-income countries.BMJ global health · 2025Article
- Evaluating the role of observational uncertainty in climate impact assessments: Temperature-driven yellow fever risk in South America.PLOS climate · 2025Article
- Fatal yellow fever among captive non-human primates in southern Colombia, 2025.Frontiers in veterinary science · 2025Article
- Mechanistic yellow fever modelling under climate change in Brazil and beyond: Information gaps and future steps.Wellcome open research · 2025Article
- Yellow fever's distressing return: a wake-up call for public health in the Americas.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Yellow fever (YF), a vector-borne viral hemorrhagic fever, is endemic in tropical regions of Africa and South America, with large vaccination programmes being used for control. However, significant outbreaks have occurred in recent years. Data on infection rates and seroprevalence is often sparse, requiring robust mathematical models to estimate the burden of yellow fever. In particular, modelling is required to estimate the risk of outbreaks and inform policy decisions regarding the targeting of vaccination. We present a dynamic, stochastic model of YF transmission which uses environmental covariates to estimate the force of infection due to spillover from the sylvatic (non-human primate) reservoir and the basic reproduction number for human-to-human transmission. We examine the potential for targets identified by the World Health Organization EYE Strategy (50%, 60% or 80% vaccination coverage in 1-60 year olds) to achieve different threshold values for the effective reproduction number. Threshold values are chosen to reflect the potential for seasonal and/or climatic variation in YF transmission even in a scenario where vaccination lowers the median reproduction number below 1. Based on parameter estimates derived from epidemiological data, it is found that the 2022 EYE Strategy target coverage is sufficient to reduce the static averaged annual effective reproduction number R below 1 across most or all regions in Africa depending on the effectiveness of reported vaccinations, but insufficient to reduce it below 0.5 and thereby eliminate outbreaks in areas with high seasonal range. Coverage levels aligned with the 2026 targets are found to significantly decrease the proportion of regions where R is greater than 0.5.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.